Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
43
CUE Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-7.68%
Day range:
$0.70 - $1.03
52-week range:
$0.45 - $1.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.70x
P/B ratio:
9.80x
Volume:
6.3M
Avg. volume:
466.3K
1-year change:
-8.15%
Market cap:
$64.5M
Revenue:
$9.3M
EPS (TTM):
-$0.67
Analysts' Opinion
-
Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Cue Biopharma has an estimated upside of 367.29% from its current price of $0.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.86.
Fair Value
-
According to the consensus of 1 analyst, Cue Biopharma has 367.29% upside to fair value with a price target of $4.00 per share.
CUE vs. S&P 500
-
Over the past 5 trading days, Cue Biopharma has overperformed the S&P 500 by 9.21% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cue Biopharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cue Biopharma revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cue Biopharma reported revenues of $421K.
Earnings Growth
-
Cue Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cue Biopharma reported earnings per share of -$0.17.
Enterprise value:
54.7M
EV / Invested capital:
--
Price / LTM sales:
6.70x
EV / EBIT:
--
EV / Revenue:
6.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.57x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-103.78%
Net Income Margin (TTM):
-507.87%
Return On Equity:
-200.7%
Return On Invested Capital:
-159.08%
Operating Margin:
-2921.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $432K | $7M | $8M | $1.7M | $421K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$52.6M | -$51.3M | -$41.2M | -$12.7M | -$12.3M | |
| EBITDA | -$48.3M | -$45.3M | -$37.3M | -$11.3M | -$11.2M | |
| Diluted EPS | -$1.35 | -$1.07 | -$0.67 | -$0.25 | -$0.17 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.4M | $75.9M | $68.8M | $44.7M | $15.9M | |
| Total Assets | $88.7M | $90.7M | $81.7M | $54M | $22.3M | |
| Current Liabilities | $16.6M | $11.4M | $13.8M | $18.1M | $15.5M | |
| Total Liabilities | $19.1M | $26M | $26.7M | $23.9M | $15.7M | |
| Total Equity | $69.7M | $64.7M | $55M | $30M | $6.6M | |
| Total Debt | -- | $9.9M | $10M | $7.2M | $3.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.1M | -$38.9M | -$34.7M | -$9.8M | -$8.2M | |
| Cash From Investing | -$9.6M | $9.9M | -$63K | -$55K | -$150K | |
| Cash From Financing | $38.9M | $13.8M | $6.9M | $2.4M | -$1M | |
| Free Cash Flow | -$41.2M | -$39M | -$34.9M | -$9.8M | -$8.3M | |
CUE
Sector
Market Cap
$64.5M
$34.4M
Price % of 52-Week High
43.04%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-17.6%
-1.01%
1-Year Price Total Return
-8.16%
-37.36%
Beta (5-Year)
1.433
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.76
200-day SMA
Sell
Level
$1.03
Bollinger Bands (100)
Buy
Level
0.63 - 1.01
Chaikin Money Flow
Sell
Level
-83.6K
20-day SMA
Buy
Level
$0.72
Relative Strength Index (RSI14)
Buy
Level
63.03
ADX Line
Buy
Level
26.84
Williams %R
Neutral
Level
-45.7895
50-day SMA
Buy
Level
$0.70
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
8.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-15.4887)
Sell
CA Score
(Annual)
Level (-3.8459)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.291)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Stock Forecast FAQ
In the current month, CUE has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CUE average analyst price target in the past 3 months is $4.00.
-
Where Will Cue Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cue Biopharma share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Cue Biopharma?
Analysts are divided on their view about Cue Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cue Biopharma is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Cue Biopharma's Price Target?
The price target for Cue Biopharma over the next 1-year time period is forecast to be $4.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cue Biopharma is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CUE?
You can purchase shares of Cue Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cue Biopharma shares.
-
What Is The Cue Biopharma Share Price Today?
Cue Biopharma was last trading at $0.84 per share. This represents the most recent stock quote for Cue Biopharma. Yesterday, Cue Biopharma closed at $0.86 per share.
-
How To Buy Cue Biopharma Stock Online?
In order to purchase Cue Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
